CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 270 enrolled
Drug / intervention
ISV-403 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00622908
NCT00622908Phase 2Completed
CompareCT.gov

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis

Bausch & Lomb Incorporated·interventional·Posted Feb 25, 2008·Updated Mar 24, 2015

In Brief

A Phase 2 clinical trial evaluating ISV-403 and Vehicle for Bacterial Conjunctivitis. Completed, enrolled 270 participants.

Detailed Summary

To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 25, 2008
Enrollment StartDec 1, 2004
Primary CompletionJun 1, 2005
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.4 years ago

Interventions

ISV-403drug

0.6% TID, 5 days

Vehicledrug

Vehicle of ISV-403 TID, 5 days